aTyr Pharma (NASDAQ:ATYR) Stock Price Up 7.6% - What's Next?

aTyr Pharma, Inc. (NASDAQ:ATYR - Get Free Report)'s stock price rose 7.6% during mid-day trading on Friday . The company traded as high as $6.37 and last traded at $6.23. Approximately 489,282 shares traded hands during trading, a decline of 64% from the average daily volume of 1,352,841 shares. The stock had previously closed at $5.79.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. HC Wainwright restated a "buy" rating and set a $35.00 target price on shares of aTyr Pharma in a research note on Wednesday, June 4th. Wells Fargo & Company increased their price objective on shares of aTyr Pharma from $17.00 to $25.00 and gave the stock an "overweight" rating in a research note on Friday, June 20th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $20.20.

aTyr Pharma Stock Up 5.8%

The company has a current ratio of 7.79, a quick ratio of 7.79 and a debt-to-equity ratio of 0.01. The company has a 50 day simple moving average of $4.76 and a two-hundred day simple moving average of $3.92. The firm has a market capitalization of $545.13 million, a P/E ratio of -7.57 and a beta of 0.89.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.02. On average, equities analysts predict that aTyr Pharma, Inc. will post -0.91 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. grew its position in aTyr Pharma by 46.0% in the first quarter. Goldman Sachs Group Inc. now owns 382,317 shares of the company's stock worth $1,155,000 after acquiring an additional 120,496 shares in the last quarter. Octagon Capital Advisors LP increased its position in aTyr Pharma by 294.7% during the first quarter. Octagon Capital Advisors LP now owns 3,552,000 shares of the company's stock valued at $10,727,000 after acquiring an additional 2,652,000 shares during the last quarter. Millennium Management LLC raised its stake in shares of aTyr Pharma by 334.5% in the first quarter. Millennium Management LLC now owns 1,599,041 shares of the company's stock valued at $4,829,000 after acquiring an additional 1,231,052 shares during the period. Ally Bridge Group NY LLC lifted its holdings in shares of aTyr Pharma by 11.0% in the 1st quarter. Ally Bridge Group NY LLC now owns 777,020 shares of the company's stock worth $2,347,000 after acquiring an additional 77,290 shares during the last quarter. Finally, MAI Capital Management boosted its stake in shares of aTyr Pharma by 306,100.0% during the 1st quarter. MAI Capital Management now owns 658,330 shares of the company's stock worth $1,988,000 after purchasing an additional 658,115 shares during the period. Hedge funds and other institutional investors own 61.72% of the company's stock.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.